Nectin-4 is expressed in 69% of solid tumors [563] and overexpressed in more than 60% of bladder cancers (or urothelial carcinomas) [563, 570], making it an attractive target for urothelial carcinoma treatment. The gene discussed is NECTIN4; the disease is urothelial carcinoma.